Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Tuberculosis

  Free Subscription


Articles published in Int J Tuberc Lung Dis

Retrieve available abstracts of 410 articles:
HTML format



Single Articles


    June 2022
  1. LAZARCHIK A, Nyaruhirira AU, Chiang CY, Wares F, et al
    Global availability of susceptibility testing for second-line anti-tuberculosis agents.
    Int J Tuberc Lung Dis. 2022;26:524-528.
    PubMed     Abstract available


  2. PELZER PT, Smit Y, Tiemersma EW, Huong NT, et al
    Does BCG vaccination protect against infection with M. tuberculosis?
    Int J Tuberc Lung Dis. 2022;26:529-536.
    PubMed     Abstract available


  3. SINHA P, Bhargava A, Carwile M, Cintron C, et al
    Undernutrition can no longer be an afterthought for global efforts to eliminate TB.
    Int J Tuberc Lung Dis. 2022;26:477-480.
    PubMed    


  4. BOEKELHEIDE K, Olugbosi M, Nedelman J, Everitt D, et al
    Male reproductive hormones in patients treated with pretomanid.
    Int J Tuberc Lung Dis. 2022;26:558-565.
    PubMed     Abstract available


  5. KANIGA K, Lounis N, Zhuo S, Bakare N, et al
    Impact of Rv0678 mutations on patients with drug-resistant TB treated with bedaquiline.
    Int J Tuberc Lung Dis. 2022;26:571-573.
    PubMed    


  6. LAURSEN LL, Dahl VN, Wejse C
    Stool testing for pulmonary TB diagnosis in adults.
    Int J Tuberc Lung Dis. 2022;26:516-523.
    PubMed     Abstract available


  7. SHIN AY, Jekarl DW, Kim HW, Ha JH, et al
    Early line-probe assay using DNA specimens in patients with pulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:509-515.
    PubMed     Abstract available


  8. NAUFAL F, Chaisson LH, Robsky KO, Delgado-Barroso P, et al
    Number needed to screen for TB in clinical, structural or occupational risk groups.
    Int J Tuberc Lung Dis. 2022;26:500-508.
    PubMed     Abstract available


  9. MALIK AA, Amanullah F
    Source case investigation can reduce the diagnostic gap for childhood TB.
    Int J Tuberc Lung Dis. 2022;26:566-567.
    PubMed    


    May 2022
  10. GRANOZZI B, Bisognin F, Lombardi G, Dal Monte P, et al
    TB mortality in low-incidence countries: can we reduce it further?
    Int J Tuberc Lung Dis. 2022;26:467-469.
    PubMed    


  11. GROSCHEL MI, van den Boom M, Dixit A, Skrahina A, et al
    Management of childhood MDR-TB in Europe and Central Asia: report of a Regional WHO meeting.
    Int J Tuberc Lung Dis. 2022;26:433-440.
    PubMed     Abstract available


  12. SHAMPUTA IC, Nguyen DTK, Burdo T, Dao G, et al
    Canadian immigrants awareness and perceptions of TB infection and TB.
    Int J Tuberc Lung Dis. 2022;26:454-456.
    PubMed    


  13. COOREY NJ, Kensitt L, Davies J, Keller E, et al
    Risk factors for TB in Australia and their association with delayed treatment completion.
    Int J Tuberc Lung Dis. 2022;26:399-405.
    PubMed     Abstract available


  14. KRITSKI AL, Viveiros M, Carvalho ACC
    Rapid molecular diagnostics to detect resistance to second-line anti-TB drugs.
    Int J Tuberc Lung Dis. 2022;26:385-387.
    PubMed    


  15. GANDHI R, Deepak KG, Verma G, Chaubey S, et al
    Engaging private pharmacies to help end TB in India.
    Int J Tuberc Lung Dis. 2022;26:457-459.
    PubMed    


  16. NINAN MM, Rupali P, Varghese GM, Shalini EB, et al
    Xpert Ultra in diagnosing extrapulmonary TB: accuracy and trace calls.
    Int J Tuberc Lung Dis. 2022;26:441-445.
    PubMed     Abstract available


  17. MALIK AA, Hussain H
    Preventive treatment for MDR-TB exposure in households.
    Int J Tuberc Lung Dis. 2022;26:466-467.
    PubMed    


  18. CAPEDING TPJ, Rosa JD, Lam H, Gaviola DG, et al
    Cost of TB prevention and treatment in the Philippines in 2017.
    Int J Tuberc Lung Dis. 2022;26:392-398.
    PubMed     Abstract available


  19. PALANI N, Premkumar M, Vaishnavee V, Dinesh V, et al
    Trends in rifampicin and isoniazid resistance in patients with presumptive TB.
    Int J Tuberc Lung Dis. 2022;26:446-453.
    PubMed     Abstract available


    April 2022
  20. MARCHESE V, Formenti B, Marchese L, Gregori N, et al
    COVID-19 effect on TB presentation and outcome.
    Int J Tuberc Lung Dis. 2022;26:375-377.
    PubMed    


  21. KIM JW, Vella C, Parvez W, Verma R, et al
    Impact of COVID-19 on the diagnosis and management of lung cancer and TB.
    Int J Tuberc Lung Dis. 2022;26:372-374.
    PubMed    


  22. ALLORANT A, Biswas S, Ahmed S, Wiens KE, et al
    Finding gaps in routine TB surveillance activities in Bangladesh.
    Int J Tuberc Lung Dis. 2022;26:356-362.
    PubMed     Abstract available


  23. SHIVAKUMAR SVBY, Padmapriyadarsini C, Chavan A, Paradkar M, et al
    Concomitant pulmonary disease is common among patients with extrapulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:341-347.
    PubMed     Abstract available


  24. HUGHES G, Bern H, Chiang CY, Goodall RL, et al
    QT prolongation in the STREAM Stage 1 Trial.
    Int J Tuberc Lung Dis. 2022;26:334-340.
    PubMed     Abstract available


  25. DEN BOON S, Lienhardt C, Zignol M, Schwartzman K, et al
    WHO target product profiles for TB preventive treatment.
    Int J Tuberc Lung Dis. 2022;26:302-309.
    PubMed     Abstract available


  26. ADAMASHVILI N, Baliashvili D, Kuchukhidze G, Salindri AD, et al
    Low BMI increases all-cause mortality rates in patients with drug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:326-333.
    PubMed     Abstract available


  27. PRADHAN NN, Paradkar MS, Kagal A, Valvi C, et al
    Performance of Xpert((R)) MTB/RIF and Xpert((R)) Ultra for the diagnosis of tuberculous meningitis in children.
    Int J Tuberc Lung Dis. 2022;26:317-325.
    PubMed     Abstract available


  28. DOWDY DW, Islam MA
    Finding TB s "missing millions", one district at a time.
    Int J Tuberc Lung Dis. 2022;26:295.
    PubMed    


    March 2022
  29. SUMNER T, Jensen HT, Keogh-Brown MR, Vassall A, et al
    Time to integrate epidemiological and economic models for TB.
    Int J Tuberc Lung Dis. 2022;26:282-284.
    PubMed    


  30. MBELELE PM, Sabiiti W, Heysell SK, Sauli E, et al
    Use of a molecular bacterial load assay to distinguish between active TB and post-TB lung disease.
    Int J Tuberc Lung Dis. 2022;26:276-278.
    PubMed    


  31. MUSONDA HK, Rose PC, Switala J, Schaaf HS, et al
    Paediatric admissions to a TB hospital: reasons for admission, clinical profile and outcomes.
    Int J Tuberc Lung Dis. 2022;26:217-223.
    PubMed     Abstract available


  32. MIGLIORI GB, Wu SJ, Matteelli A, Zenner D, et al
    Clinical standards for the diagnosis, treatment and prevention of TB infection.
    Int J Tuberc Lung Dis. 2022;26:190-205.
    PubMed     Abstract available


    February 2022
  33. TINOCO EM, Vasconcelos A, Alves F, Duarte R, et al
    Impact of COVID-19 on extrapulmonary TB and the benefit of decentralised TB services.
    Int J Tuberc Lung Dis. 2022;26:178-180.
    PubMed    


  34. ORTIZ-MARTINEZ Y, Rodriguez-Morales AJ, Henao-Martinez AF
    Decreased notification of TB cases during the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2022;26:177-178.
    PubMed    


  35. SCHIZA V, Kruse M, Xiao Y, Kar S, et al
    Impact of the COVID-19 pandemic on TB infection testing.
    Int J Tuberc Lung Dis. 2022;26:174-176.
    PubMed    


  36. GUREVA T, Turkova A, Yablokova E, Smirnova P, et al
    Fluoroquinolone preventive therapy for children exposed to MDR-TB.
    Int J Tuberc Lung Dis. 2022;26:171-173.
    PubMed    


  37. BOHLBRO AS, Patsche CB, Mendes AM, Sifna A, et al
    A self-rated health score predicts severe disease and high mortality in patients with pulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:158-165.
    PubMed     Abstract available


  38. MOHR-HOLLAND E, Daniels J, Reuter A, Rodriguez CA, et al
    Early mortality during rifampicin-resistant TB treatment.
    Int J Tuberc Lung Dis. 2022;26:150-157.
    PubMed     Abstract available


  39. BEAUMONT AL, Doumbia A, Chateau N, Meynard JL, et al
    Why are people still dying of drug-susceptible TB in Paris in the 21(st) century?
    Int J Tuberc Lung Dis. 2022;26:142-149.
    PubMed     Abstract available


  40. LOPEZ-VARELA E, Garcia-Prats AJ, Seddon JA, Draper HR, et al
    Treatment outcomes and safety in children with rifampicin-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:133-141.
    PubMed     Abstract available


  41. BURHAN E, Soepandi PZ, Isbaniah F, Damayanti K, et al
    Determinants of treatment outcomes in patients with multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:126-132.
    PubMed     Abstract available


  42. HOSSAIN MD, Rahim MA, Islam N, Afroze F, et al
    TB prevalence among patients with diabetes in Bangladesh.
    Int J Tuberc Lung Dis. 2022;26:119-125.
    PubMed     Abstract available


  43. KHAWCHAROENPORN T, Noisang K
    Incomplete contact investigation and risk of developing TB among healthcare professionals.
    Int J Tuberc Lung Dis. 2022;26:111-118.
    PubMed     Abstract available


  44. APRIANI L, Koesoemadinata RC, Bastos ML, Wulandari DA, et al
    Implementing the 4R and 9H regimens for TB preventive treatment in Indonesia.
    Int J Tuberc Lung Dis. 2022;26:103-110.
    PubMed     Abstract available


  45. ILAIWY G, Heysell SK, Thomas TA
    National approaches to TB care in adolescents.
    Int J Tuberc Lung Dis. 2022;26:96-102.
    PubMed     Abstract available


  46. SILVA DR, de Queiroz Mello FC
    Improving outcomes for multidrug-resistant TB treatment.
    Int J Tuberc Lung Dis. 2022;26:93-95.
    PubMed    


  47. BARRETT J
    Why are people still dying from TB in low-burden countries?
    Int J Tuberc Lung Dis. 2022;26:91-92.
    PubMed    


  48. HARRIES AD, Zellweger JP
    Protecting healthcare workers from TB.
    Int J Tuberc Lung Dis. 2022;26:89-90.
    PubMed    


  49. GRAHAM SM, Amanullah F
    Updated guidelines for child and adolescent TB.
    Int J Tuberc Lung Dis. 2022;26:81-84.
    PubMed    


  50. LANGE C, Kay A, Mandalakas AM
    The need for effective drugs for TB prevention: set your goals high, and don t stop till you get there.
    Int J Tuberc Lung Dis. 2022;26:85-88.
    PubMed    


    January 2022
  51. TADOLINI M, Onozaki I
    National TB prevalence surveys in the COVID-19 era.
    Int J Tuberc Lung Dis. 2022;26:4-5.
    PubMed    


  52. SINHA P, White LF, Hochberg NS, Cegielski JP, et al
    Avoiding pitfalls in calculating the population attributable fraction of undernutrition for TB.
    Int J Tuberc Lung Dis. 2022;26:80.
    PubMed    


  53. KLAOS K, Holicka Y, Groenheit R, Kodmon C, et al
    Current state of national TB laboratory networks in Europe: achievements and challenges.
    Int J Tuberc Lung Dis. 2022;26:71-73.
    PubMed    


  54. OJUAWO O, Piracha S, Irshad S, Mirza M, et al
    Tuberculous mastitis in a low-incidence setting: should respiratory physicians be concerned?
    Int J Tuberc Lung Dis. 2022;26:69-70.
    PubMed    


  55. PETRUCCIOLI E, Farroni C, Cuzzi G, Vanini V, et al
    VIDAS((R)) TB-IGRA reagents induce a CD4(+) and CD8(+) T-cell IFN-gamma response for both TB infection and active TB.
    Int J Tuberc Lung Dis. 2022;26:65-68.
    PubMed    


  56. CHIPINDURO M, Timire C, Chirenda J, Matambo R, et al
    TB prevalence in Zimbabwe: a national cross-sectional survey, 2014.
    Int J Tuberc Lung Dis. 2022;26:57-64.
    PubMed     Abstract available


  57. ACOSTA J, Flores P, Alarcon M, Grande-Ortiz M, et al
    A randomised controlled trial to evaluate a medication monitoring system for TB treatment.
    Int J Tuberc Lung Dis. 2022;26:44-49.
    PubMed     Abstract available


    December 2021
  58. ZAMANI S, Honarvar MR, Behnampour N, Sheikhy M, et al
    Decline in TB incidence during the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2021;25:1043-1044.
    PubMed    


  59. SUMNER T, Fiore-Gartland A, Hatherill M, Houben RMGJ, et al
    The effect of new Mycobacterium tuberculosis infection on the sensitivity of prognostic TB signatures.
    Int J Tuberc Lung Dis. 2021;25:1001-1005.
    PubMed     Abstract available


  60. SARDA R, Ray A
    Pulmonary TB and chronic pulmonary aspergillosis.
    Int J Tuberc Lung Dis. 2021;25:1042-1043.
    PubMed    


  61. TESFAHUN H, Moussally K, Al-Ani NA, Al-Salhi LG, et al
    Introduction of new drugs for drug-resistant TB in Iraq.
    Int J Tuberc Lung Dis. 2021;25:1041-1042.
    PubMed    


  62. CHATTERJEE S, Toshniwal MN, Bhide P, Sachdeva KS, et al
    Costs of TB services in India (No 1).
    Int J Tuberc Lung Dis. 2021;25:1013-1018.
    PubMed     Abstract available


  63. ZHU H, Xie L, Liu ZQ, Wang B, et al
    Population pharmacokinetics of bedaquiline in patients with drug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:1006-1012.
    PubMed     Abstract available


  64. NIKOLENKA A, Mansjo M, Skrahina A, Hurevich H, et al
    Whole-genome sequencing differentiates relapse from re-infection in TB.
    Int J Tuberc Lung Dis. 2021;25:995-1000.
    PubMed     Abstract available


  65. LEE JJ, Kang HY, Lee WI, Cho SY, et al
    Efflux pump gene expression study using RNA-seq in multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:974-981.
    PubMed     Abstract available


  66. TELISINGHE L, Shaweno D, Hayes RJ, Dodd PJ, et al
    The effect of systematic screening of the general population on TB case notification rates.
    Int J Tuberc Lung Dis. 2021;25:964-973.
    PubMed     Abstract available


    November 2021
  67. ANTONY S, Bodhanwala M, Shah I
    Clinical profile and outcomes of paediatric central nervous system tuberculomas.
    Int J Tuberc Lung Dis. 2021;25:953-955.
    PubMed    


  68. FUKUSHIMA K, Akagi K, Kondoh A, Kubo T, et al
    Evaluation of QFT-Plus performance using blood samples stored at room temperature.
    Int J Tuberc Lung Dis. 2021;25:948-949.
    PubMed    


  69. WOLTERS BA, Aartsma Y, Jansen K, van Hest R, et al
    Travel history and challenges of screening for latent TB infection in child asylum seekers.
    Int J Tuberc Lung Dis. 2021;25:945-947.
    PubMed    


  70. CHRISTOPHER DJ, Coelho V, Ebby GS, Shankar D, et al
    Incremental yield of Xpert((R)) MTB/RIF Ultra over Xpert((R)) MTB/RIF in the diagnosis of extrapulmonary TB.
    Int J Tuberc Lung Dis. 2021;25:939-944.
    PubMed     Abstract available


  71. GATECHOMPOL S, Sophonphan J, Kerr SJ, Ubolyam S, et al
    Monocyte-to-lymphocyte ratio as a predictor of TB among people living with HIV.
    Int J Tuberc Lung Dis. 2021;25:933-938.
    PubMed     Abstract available


  72. KASWA M, Minga G, Nkiere N, Mingiedi B, et al
    The economic burden of TB-affected households in DR Congo.
    Int J Tuberc Lung Dis. 2021;25:923-932.
    PubMed     Abstract available


  73. STIEBER F, Howard J, Manissero D, Boyle J, et al
    Evaluation of a lateral-flow nanoparticle fluorescence assay for TB infection diagnosis.
    Int J Tuberc Lung Dis. 2021;25:917-922.
    PubMed     Abstract available


  74. MURITHI W, Click ES, McCarthy KD, Okeyo E, et al
    Need for caution when interpreting Xpert((R)) MTB/RIF results for rifampin resistance among children.
    Int J Tuberc Lung Dis. 2021;25:911-916.
    PubMed     Abstract available


  75. LUAN L, Fraisse P, Cordel H, Charlois C, et al
    Screening for active and latent TB among migrants in France.
    Int J Tuberc Lung Dis. 2021;25:903-910.
    PubMed     Abstract available


  76. WINCKLER JL, Schaaf HS, Draper HR, McIlleron H, et al
    Pharmacokinetics of high-dose isoniazid in children affected by multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:896-902.
    PubMed     Abstract available


  77. TAAFFE J, Croda J, Moultrie H, Silva DS, et al
    Advancing TB research using digitized programmatic data.
    Int J Tuberc Lung Dis. 2021;25:890-895.
    PubMed     Abstract available


  78. BOEREE MJ, Lange C, Thwaites G, Paton N, et al
    UNITE4TB: a new consortium for clinical drug and regimen development for TB.
    Int J Tuberc Lung Dis. 2021;25:886-889.
    PubMed    


  79. OCHERETINA O, Brandao AP, Pang Y, Rodrigues C, et al
    Impact of the bacillary load on the accuracy of rifampicin resistance results by Xpert((R)) MTB/RIF.
    Int J Tuberc Lung Dis. 2021;25:881-885.
    PubMed    


  80. ALFFENAAR JC, Marais BJ, Thomas TA
    Is a high dose sufficient to achieve high isoniazid exposure in children affected by multidrug-resistant TB?
    Int J Tuberc Lung Dis. 2021;25:879-880.
    PubMed    


    October 2021
  81. SEKANDI JN, Tucker EG, Zalwango S, Buregyeya E, et al
    Digital technologies and loss to follow-up for TB patients.
    Int J Tuberc Lung Dis. 2021;25:871-872.
    PubMed    


  82. HASSAN L, Ali SM, Iqbal W, Baig S, et al
    Automated detection and reduction of stigma in online discussions about TB.
    Int J Tuberc Lung Dis. 2021;25:869-870.
    PubMed    


  83. ARENAS-MIRAS M, Sanchez-Martinez F, Jove-Caballe N, Villar-Garcia J, et al
    Clinical experience of TB in patients treated with anti-TNF-alpha.
    Int J Tuberc Lung Dis. 2021;25:866-868.
    PubMed    


  84. TAHSEEN S, Khanzada FM, Hussain A, Akhtar N, et al
    Phenotypic vs. genotypic resistance to fluoroquinolones in rifampicin-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:861-863.
    PubMed    


  85. EJO M, Van Deun A, Nunn A, Meredith S, et al
    Effectiveness of GenoType MTBDRsl in excluding TB drug resistance in a clinical trial.
    Int J Tuberc Lung Dis. 2021;25:839-845.
    PubMed     Abstract available


  86. BLACK M, Da Silva P, Scott L
    Rifampicin-resistant TB: discordance between Xpert((R)) MTB/RIF and MTBDRplus results.
    Int J Tuberc Lung Dis. 2021;25:832-838.
    PubMed     Abstract available


  87. OXLADE O, den Boon S, Menzies D, Falzon D, et al
    TB preventive treatment in high- and intermediate-incidence countries: research needs for scale-up.
    Int J Tuberc Lung Dis. 2021;25:823-831.
    PubMed     Abstract available


  88. PURCHASE S, Batist E, Mmile N, Nkosi S, et al
    Challenges in recruiting children to a multidrug-resistant TB prevention trial.
    Int J Tuberc Lung Dis. 2021;25:814-822.
    PubMed     Abstract available


    September 2021
  89. KOZINSKA M, Podlasin R, Ropelewska-Lacka K, Wojtycha-Kwasnica B, et al
    TB and COVID-19 coinfection.
    Int J Tuberc Lung Dis. 2021;25:776-777.
    PubMed    


  90. MOHR-HOLLAND E, Hacking D, Daniels J, Scott V, et al
    Diagnosis patterns for rifampicin-resistant TB after onset of COVID-19.
    Int J Tuberc Lung Dis. 2021;25:772-775.
    PubMed    


  91. GIGANTE AR, Sousa M, Aguiar A, Pinto M, et al
    The impact of COVID-19 on the TB response: data from the field.
    Int J Tuberc Lung Dis. 2021;25:769-771.
    PubMed    


  92. SHIN JE, Jo KW, O YJ, Jeon D, et al
    Impact of revised definitions for extensively drug-resistant TB on disease classification.
    Int J Tuberc Lung Dis. 2021;25:766-768.
    PubMed    


  93. GUTIERREZ A, Isidro A, Herrerin J, Hinojosa J, et al
    Meningeal TB in a mummified child from 4,000 years ago.
    Int J Tuberc Lung Dis. 2021;25:761-762.
    PubMed    


  94. KAMOLWAT P, Nonghanphithak D, Chaiprasert A, Smithtikarn S, et al
    Diagnostic performance of whole-genome sequencing for identifying drug-resistant TB in Thailand.
    Int J Tuberc Lung Dis. 2021;25:754-760.
    PubMed     Abstract available


  95. HUDDART S, Ingawale P, Edwin J, Jondhale V, et al
    TB case fatality and recurrence in a private sector cohort in Mumbai, India.
    Int J Tuberc Lung Dis. 2021;25:738-746.
    PubMed     Abstract available


  96. MOODLIAR R, Aksenova V, Frias MVG, van de Logt J, et al
    Bedaquiline for multidrug-resistant TB in paediatric patients.
    Int J Tuberc Lung Dis. 2021;25:716-724.
    PubMed     Abstract available


  97. MURPHY RA, Douglas-Jones B, Mucinya G, Sunpath H, et al
    Expanding the use of dolutegravir-based antiretroviral therapy in multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:696-700.
    PubMed     Abstract available


  98. CHESOV D, Makhanda G, Furin J
    Tackling the many layers of stigma is essential for the "End TB Strategy".
    Int J Tuberc Lung Dis. 2021;25:683-684.
    PubMed    


    August 2021
  99. RANAIVOMANANA P, Knoblauch AM, Razafimahatratra MC, Raherinandrasana AH, et al
    Pulmonary and pleural TB prevalence in pregnant women.
    Int J Tuberc Lung Dis. 2021;25:668-670.
    PubMed    


  100. EDDY JJ, Seth B, White LF, Sulis CA, et al
    Decreasing time spent in airborne infection isolation during TB testing.
    Int J Tuberc Lung Dis. 2021;25:665-667.
    PubMed    


  101. CLARKSON MC, McQuaid CF, Houben RM, Kranzer K, et al
    Better data for country-level TB resource allocation are urgently required.
    Int J Tuberc Lung Dis. 2021;25:662-664.
    PubMed    


  102. PERRY A, Chitnis A, Chin A, Hoffmann C, et al
    Real-world implementation of video-observed therapy in an urban TB program in the United States.
    Int J Tuberc Lung Dis. 2021;25:655-661.
    PubMed     Abstract available


  103. SMITH AGC, Gujabidze M, Avaliani T, Blumberg HM, et al
    Clinical outcomes among patients with tuberculous meningitis receiving intensified treatment regimens.
    Int J Tuberc Lung Dis. 2021;25:632-639.
    PubMed     Abstract available


  104. SHARMA K, Sharma M, Modi M, Singla N, et al
    Comparative analysis of Truenat MTB Plus and Xpert((R)) Ultra in diagnosing tuberculous meningitis.
    Int J Tuberc Lung Dis. 2021;25:626-631.
    PubMed     Abstract available


  105. CAMPBELL JR, Katamba A, Oxlade O, Schwartzman K, et al
    Improving country-level modelling to support TB prevention and care.
    Int J Tuberc Lung Dis. 2021;25:607-608.
    PubMed    


  106. DONOVAN J, Walker TM
    Diagnosing tuberculous meningitis: a testing process.
    Int J Tuberc Lung Dis. 2021;25:605-606.
    PubMed    


    July 2021
  107. AMOUR M, von Reyn CF
    A new paradigm: testing household contacts of adolescents with incident TB infection.
    Int J Tuberc Lung Dis. 2021;25:599b-600.
    PubMed    


  108. RODRIGUEZ CA, Brooks MB, Aibana O, Mitnick CD, et al
    Sputum culture conversion definitions and analytic practices for multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:596-598.
    PubMed    


  109. ERISA KC, Robsky KO, Kitonsa PJ, Nalutaaya A, et al
    Low prevalence of diabetes mellitus in TB patients and the community in urban Uganda.
    Int J Tuberc Lung Dis. 2021;25:590-592.
    PubMed    


  110. DOUGLAS-JONES B, Mohr-Holland E, Mema N, Mathee S, et al
    A home-based care programme for rifampicin-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:587-589.
    PubMed    


  111. HABIB SS, Malik AA, Khan U, Khowaja S, et al
    Impact of upfront Xpert testing on time to treatment initiation for multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:584-586.
    PubMed    


  112. MORAN A, Lebona L, Makgopa G, Nkwane Y, et al
    One size does not fit all: reaching agricultural workers in South Africa with TB services.
    Int J Tuberc Lung Dis. 2021;25:573-578.
    PubMed     Abstract available


  113. YANGTHARA B, Wutthigate P, Roongmaitree S, Siripattanapipong P, et al
    Nosocomial TB in two neonatal intensive care units at a tertiary care centre: infection risk and outcomes.
    Int J Tuberc Lung Dis. 2021;25:567-572.
    PubMed     Abstract available


  114. BLACK DA, McBrien SW, Gersh J, Ghassemieh B, et al
    TB risk by time since U.S. entry among non-U.S.-born residents of Washington State, USA.
    Int J Tuberc Lung Dis. 2021;25:560-566.
    PubMed     Abstract available


  115. FEUTH T, Patovirta RL, Grierson S, Danilovits M, et al
    Costs of multidrug-resistant TB treatment in Finland and Estonia affected by the 2019 WHO guidelines.
    Int J Tuberc Lung Dis. 2021;25:554-559.
    PubMed     Abstract available


  116. LARGEN A, Ayala A, Khurana R, Katz DJ, et al
    Evaluation of point-of-care algorithms to detect diabetes during screening for latent TB infection.
    Int J Tuberc Lung Dis. 2021;25:547-553.
    PubMed     Abstract available


  117. BALUKU JB, Nuwagira E, Bongomin F, Denning DW, et al
    Pulmonary TB and chronic pulmonary aspergillosis: clinical differences and similarities.
    Int J Tuberc Lung Dis. 2021;25:537-546.
    PubMed     Abstract available


  118. SHARMA M, Onozaki I, Nunn P
    TB in older people in Asia: why it is important.
    Int J Tuberc Lung Dis. 2021;25:521-524.
    PubMed    


  119. SALZER HJF, Wang JY
    Chronic pulmonary aspergillosis as a sequel to pulmonary TB.
    Int J Tuberc Lung Dis. 2021;25:519-520.
    PubMed    


    June 2021
  120. AGOSTINIS A, Heffernan C, Long R, Beckon A, et al
    Interferon-gamma release assays for latent tuberculosis infection screening in Canadian federal correctional facilities.
    Int J Tuberc Lung Dis. 2021;25:447-452.
    PubMed     Abstract available


  121. TEO AKJ, Ong CWM, Hsu LY
    COVID-19 and TB: a progression-regression conundrum.
    Int J Tuberc Lung Dis. 2021;25:421-423.
    PubMed    


  122. BASHAM CA, Romanowski K, Johnston JC
    Alcohol use disorder and TB survivor health.
    Int J Tuberc Lung Dis. 2021;25:516-517.
    PubMed    


  123. MANTSHONYANE L, Kgwaadira B, Gross R
    The absence of evidence of cure is not a risk for recurrent TB among patients treated for TB.
    Int J Tuberc Lung Dis. 2021;25:511-512.
    PubMed    


  124. ROYCROFT E, Fitzgibbon MM, Kelly DM, Scully M, et al
    The largest prison outbreak of TB in Western Europe investigated using whole-genome sequencing.
    Int J Tuberc Lung Dis. 2021;25:491-497.
    PubMed     Abstract available


  125. SZKWARKO D, Amisi JA, Peterson D, Burudi S, et al
    Using a mobile application to improve pediatric presumptive TB identification in western Kenya.
    Int J Tuberc Lung Dis. 2021;25:468-474.
    PubMed     Abstract available


  126. REDWOOD L, Mitchell EMH, Viney K, Snow K, et al
    Depression, stigma and quality of life in people with drug-susceptible TB and drug-resistant TB in Vietnam.
    Int J Tuberc Lung Dis. 2021;25:461-467.
    PubMed     Abstract available


  127. OELOFSE S, Esmail A, Diacon AH, Conradie F, et al
    Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts.
    Int J Tuberc Lung Dis. 2021;25:453-460.
    PubMed     Abstract available


  128. CHAISSON LH, Naufal F, Delgado-Barroso P, Alvarez-Manzo HS, et al
    A systematic review of the number needed to screen for active TB among people living with HIV.
    Int J Tuberc Lung Dis. 2021;25:427-435.
    PubMed     Abstract available


  129. TAVOSCHI L, Toscanini F, Pontali E
    TB and prisons: confinement does not contain the disease.
    Int J Tuberc Lung Dis. 2021;25:424-426.
    PubMed    


  130. AKKERMAN OW, Tiberi S, Alffenaar JW
    Shortening MDR-TB treatment: is treating more patients with fewer drugs better?
    Int J Tuberc Lung Dis. 2021;25:419-420.
    PubMed    


    May 2021
  131. ZOKUFA N, Lebelo K, Hacking D, Tabo L, et al
    Community-based TB testing as an essential part of TB recovery plans in the COVID-19 era.
    Int J Tuberc Lung Dis. 2021;25:406-408.
    PubMed    


  132. POLLOCK NR, MacIntyre AT, Blauwkamp TA, Blair L, et al
    Detection of Mycobacterium tuberculosis cell-free DNA to diagnose TB in pediatric and adult patients.
    Int J Tuberc Lung Dis. 2021;25:403-405.
    PubMed    


  133. MIN J, Kang JY, Kim J, Yang J, et al
    Impact of COVID-19 on TB services in Korea.
    Int J Tuberc Lung Dis. 2021;25:400-402.
    PubMed    


  134. MARGINEANU I, Mor Z, Garcia D, Gilpin C, et al
    TB and COVID-19 in migrants - the need to focus on both conditions.
    Int J Tuberc Lung Dis. 2021;25:333-335.
    PubMed    


  135. MCQUAID CF, Foster N, Quaife M, Levy J, et al
    Digital adherence technology for TB: focus on livelihoods as well as lives.
    Int J Tuberc Lung Dis. 2021;25:416-417.
    PubMed    


  136. RICCARDI N, Saderi L, Borroni E, Tagliani E, et al
    Therapeutic strategies and outcomes of MDR and pre-XDR-TB in Italy: a nationwide study.
    Int J Tuberc Lung Dis. 2021;25:395-399.
    PubMed     Abstract available


  137. KALEMA N, Semeere A, Banturaki G, Kyamugabwa A, et al
    Gaps in TB preventive therapy for persons initiating antiretroviral therapy in Uganda: an explanatory sequential cascade analysis.
    Int J Tuberc Lung Dis. 2021;25:388-394.
    PubMed     Abstract available


  138. SATYANARAYANA S, Bhatia V, Mandal PP, Kanchar A, et al
    Urgent need to address the slow scale-up of TB preventive treatment in the WHO South-East Asia Region.
    Int J Tuberc Lung Dis. 2021;25:382-387.
    PubMed     Abstract available


  139. FERREIRO L, Ruano-Ravina A, Otero-Mallo R, Pou-Alvarez C, et al
    Recent epidemiological trends in extrapulmonary TB in Galicia, Spain.
    Int J Tuberc Lung Dis. 2021;25:373-381.
    PubMed     Abstract available


  140. WEYENGA H, Karanja M, Onyango E, Katana AK, et al
    Can isoniazid preventive therapy be scaled up rapidly? Lessons learned in Kenya, 2014-2018.
    Int J Tuberc Lung Dis. 2021;25:367-372.
    PubMed     Abstract available


  141. MARTSON AG, Kim HY, Marais B, Alffenaar JW, et al
    The importance of pharmacokinetics/pharmacodynamics assessment in Phase IIB/III trials for MDR-TB treatment.
    Int J Tuberc Lung Dis. 2021;25:336-339.
    PubMed    


    April 2021
  142. MALABAD JCM, Ang CF, Palabrica FAR, Cajucom MAM, et al
    Molecular epidemiology of Mycobacterium tuberculosis in adult Filipino TB-HIV co-infected patients.
    Int J Tuberc Lung Dis. 2021;25:285-291.
    PubMed     Abstract available


  143. HARRIES AD, Kumar AMV, Satyanarayana S, Thekkur P, et al
    TB and COVID-19: measuring key risk factors that affect treatment outcomes.
    Int J Tuberc Lung Dis. 2021;25:329-331.
    PubMed    


  144. COX V, Guglielmetti L, Hewison C, Reuter A, et al
    Reply to: "Human rights: finding the right balance for rifampicin-resistant TB treatment".
    Int J Tuberc Lung Dis. 2021;25:328-329.
    PubMed    


  145. VAN DEUN A, Piubello A, Lynen L, de Jong BC, et al
    Human rights: finding the right balance for rifampicin-resistant TB treatment.
    Int J Tuberc Lung Dis. 2021;25:327-328.
    PubMed    


  146. GULLON-BLANCO JA, Rodrigo-Sanz T, Alvarez-Navascues F, Tabernero-Huguet E, et al
    Completion of treatment for latent TB infection in a low prevalence setting.
    Int J Tuberc Lung Dis. 2021;25:321-323.
    PubMed    


  147. ROY N, Krishnamoorthy Y, Rajaa S, Ezhumalai K, et al
    Health-related quality of life and its effect on TB treatment outcomes.
    Int J Tuberc Lung Dis. 2021;25:318-320.
    PubMed    


  148. BHERING M, Duarte R, Kritski A
    Treatment outcomes and predictive factors for multidrug-resistant TB and HIV coinfection in Rio de Janeiro State, Brazil.
    Int J Tuberc Lung Dis. 2021;25:292-298.
    PubMed     Abstract available


  149. CHESOV D, Butov D, Reimann M, Heyckendorf J, et al
    Impact of lung function on treatment outcome in patients with TB.
    Int J Tuberc Lung Dis. 2021;25:277-284.
    PubMed     Abstract available


  150. VISCA D, D Ambrosio L, Centis R, Pontali E, et al
    Post-TB disease: a new topic for investigation-and why it matters.
    Int J Tuberc Lung Dis. 2021;25:258-261.
    PubMed    


  151. LAU A, Ferrara G
    Disseminated TB: still being missed and misunderstood.
    Int J Tuberc Lung Dis. 2021;25:255-257.
    PubMed    


  152. SCHULTINK MP, Kerstjens HAM, Ter Beek L, Zondag H, et al
    Assessment of TB treatment on patient well-being.
    Int J Tuberc Lung Dis. 2021;25:315-317.
    PubMed    


    March 2021
  153. KUMAR MS, Surendran D, Manu MS, Rakesh PS, et al
    Mortality due to TB-COVID-19 coinfection in India.
    Int J Tuberc Lung Dis. 2021;25:250-251.
    PubMed    


  154. GRACIAA DS, Kempker RR, Sanikidze E, Tukvadze S, et al
    TB research amidst the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2021;25:167-170.
    PubMed    


  155. ALLWOOD BW, van der Zalm MM, Mortimer K
    Reply to "Clinical care for patients with post TB lung disease".
    Int J Tuberc Lung Dis. 2021;25:253-254.
    PubMed    


  156. GUNTHER G, Ithete S
    Clinical care for patients with post-TB lung disease.
    Int J Tuberc Lung Dis. 2021;25:252-253.
    PubMed    


  157. PARK JH, Jung J, Kim JY, Hong MJ, et al
    Airborne precautions based on Xpert((R)) MTB/RIF results for patients with presumptive TB.
    Int J Tuberc Lung Dis. 2021;25:244-246.
    PubMed    


  158. KIZNY GORDON A, Tong SYC, Martinez E, Crighton T, et al
    TB genomic surveillance and data sharing in recognising contamination events.
    Int J Tuberc Lung Dis. 2021;25:241-243.
    PubMed    


  159. BAIK Y, Nalutaaya A, Kitonsa PJ, Dowdy DW, et al
    Infection status of contacts is not associated with severity of TB in the index case.
    Int J Tuberc Lung Dis. 2021;25:237-240.
    PubMed    


  160. ADANKWAH E, Arthur RA, Minadzi D, Owusu DO, et al
    Immune response against TB and non-tuberculous mycobacterial pulmonary disease.
    Int J Tuberc Lung Dis. 2021;25:234-236.
    PubMed    


  161. MALIK AA, Fuad J, Abbass W, Ikhlaque S, et al
    Preventive treatment of drug-resistant TB in a rural setting.
    Int J Tuberc Lung Dis. 2021;25:231-233.
    PubMed    


  162. CATES L, Crudu V, Codreanu A, Ciobanu N, et al
    Laboratory costs of diagnosing TB in a high multidrug-resistant TB setting.
    Int J Tuberc Lung Dis. 2021;25:228-230.
    PubMed    


  163. COX SR, Gupte AN, Thomas B, Gaikwad S, et al
    Unhealthy alcohol use independently associated with unfavorable TB treatment outcomes among Indian men.
    Int J Tuberc Lung Dis. 2021;25:182-190.
    PubMed     Abstract available


  164. SOHN H, Sweeney S, Mudzengi D, Creswell J, et al
    Determining the value of TB active case-finding: current evidence and methodological considerations.
    Int J Tuberc Lung Dis. 2021;25:171-181.
    PubMed     Abstract available


    February 2021
  165. BARRETT J, Painter H, Rajgopal A, Keane D, et al
    Increase in disseminated TB during the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2021;25:160-166.
    PubMed    


  166. ALLWOOD BW, van der Zalm MM, Mortimer K
    Reply to: Taking action to improve post-TB lung health.
    Int J Tuberc Lung Dis. 2021;25:163a-163.
    PubMed    


  167. HARRIES AD, Dlodlo RA, Brigden G, Chakaya JM, et al
    Taking action to improve post-TB lung health.
    Int J Tuberc Lung Dis. 2021;25:161-162.
    PubMed    


  168. MOLINA-MOYA B, Guglielmetti L, Bothamley G, van Leth F, et al
    Use and impact of molecular methods for detecting drug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:157-159.
    PubMed    


  169. LAW WS, Chan CKA, Leung CC
    Management of latent TB infection in child household contacts aged under 5 years.
    Int J Tuberc Lung Dis. 2021;25:151-153.
    PubMed    


  170. MEHTA SN, Murrill M, Suryavanshi N, Bhosale R, et al
    TB-related knowledge and stigma among pregnant women in low-resource settings.
    Int J Tuberc Lung Dis. 2021;25:148-150.
    PubMed    


  171. ARSCOTT-MILLS T, Ejelonu A, Mokalane K, Machao G, et al
    One third of child TB cases were missing from the national TB register in Botswana.
    Int J Tuberc Lung Dis. 2021;25:142-144.
    PubMed    


  172. DE VOS E, Scott L, Voss De Lima Y, Warren RM, et al
    Management of rifampicin-resistant TB: programme indicators and care cascade analysis in South Africa.
    Int J Tuberc Lung Dis. 2021;25:134-141.
    PubMed     Abstract available


  173. SOTGIU G, Rosales-Klintz S, Centis R, D'Ambrosio L, et al
    TB management in the European Union/European Economic Area: a multi-centre survey.
    Int J Tuberc Lung Dis. 2021;25:126-133.
    PubMed     Abstract available


  174. FOX GJ, Johnston JC, Nguyen TA, Majumdar SS, et al
    Active case-finding in contacts of people with TB.
    Int J Tuberc Lung Dis. 2021;25:95-105.
    PubMed     Abstract available


  175. LINH NN, Miller C, Marks GB
    Potential benefits of active case finding to reduce the burden of TB.
    Int J Tuberc Lung Dis. 2021;25:93-94.
    PubMed    


    January 2021
  176. SHEN X, Sha W, Yang C, Pan Q, et al
    Continuity of TB services during the COVID-19 pandemic in China.
    Int J Tuberc Lung Dis. 2021;25:81-83.
    PubMed    



  177. TB and COVID-19 co-infection: rationale and aims of a global study.
    Int J Tuberc Lung Dis. 2021;25:78-80.
    PubMed    


  178. MAUG AKJ, Hossain MA, Gumusboga M, Decroo T, et al
    Finding the right balance between efficacy and tolerability for TB treatment: the search continues.
    Int J Tuberc Lung Dis. 2021;25:84-86.
    PubMed    


  179. PARIGI S, Venturini E, Galli L, Chiappini E, et al
    Xpert((R)) MTB/RIF Ultra performance in diagnosing paediatric pulmonary TB in gastric aspirates.
    Int J Tuberc Lung Dis. 2021;25:75-77.
    PubMed    


  180. SAKR CJ, Musharrafieh UM, Banna HS, Hoteit RA, et al
    Risks and benefits of QuantiFERON((R))-TB testing for LTBI screening of health workers.
    Int J Tuberc Lung Dis. 2021;25:72-74.
    PubMed    


  181. GENDERINI FG, Dauby N, Delforge M, De Wit S, et al
    TB in the intensive care unit in a low-endemic country.
    Int J Tuberc Lung Dis. 2021;25:69-71.
    PubMed    


  182. NABISERE R, Arinaitwe A, Muyise R, Asienzo J, et al
    Implementation of TB preventive therapy in Uganda: effect of an intervention on completion rates.
    Int J Tuberc Lung Dis. 2021;25:64-65.
    PubMed    


  183. TUCKER A, Oyuku D, Nalugwa T, Nantale M, et al
    Costs along the TB diagnostic pathway in Uganda.
    Int J Tuberc Lung Dis. 2021;25:61-63.
    PubMed    


  184. MAVE V, Kadam D, Gaikwad S, Kinikar A, et al
    Measuring TB drug levels in the hair in adults and children to monitor drug exposure and outcomes.
    Int J Tuberc Lung Dis. 2021;25:52-60.
    PubMed     Abstract available


  185. MESFIN AB, Araia ZZ, Beyene HN, Mebrahtu AH, et al
    First molecular-based anti-TB drug resistance survey in Eritrea.
    Int J Tuberc Lung Dis. 2021;25:43-51.
    PubMed     Abstract available


  186. SENEADZA NAH, Antwi S, Yang H, Enimil A, et al
    Effect of malnutrition on the pharmacokinetics of anti-TB drugs in Ghanaian children.
    Int J Tuberc Lung Dis. 2021;25:36-42.
    PubMed     Abstract available


  187. WROHAN I, Redwood L, Ho J, Velen K, et al
    Ototoxicity among multidrug-resistant TB patients: a systematic review and meta-analysis.
    Int J Tuberc Lung Dis. 2021;25:23-30.
    PubMed     Abstract available


  188. SOH AZ, Tan CTY, Mok E, Chee CBE, et al
    Adipokines and the risk of active TB: a nested case-control study.
    Int J Tuberc Lung Dis. 2021;25:31-35.
    PubMed     Abstract available


    December 2020
  189. ZHANG H, Cao X, Wang D, Xin H, et al
    The acquisition of Mycobacterium tuberculosis infection in village doctors in China: a prospective study.
    Int J Tuberc Lung Dis. 2020;24:1241-1246.
    PubMed     Abstract available


  190. FANG JL, Chao CM, Tang HJ
    The impact of COVID-19 on the diagnosis of TB in Taiwan.
    Int J Tuberc Lung Dis. 2020;24:1321-1322.
    PubMed    


  191. SINGH J, Ehtesham NZ, Hasnain SE
    Two parallel pandemics: the challenges faced by countries with COVID-19 and TB.
    Int J Tuberc Lung Dis. 2020;24:1319-1320.
    PubMed    


    November 2020
  192. FATIMA R, Yaqoob A
    In Reply: How TB and COVID-19 compare: an opportunity to integrate both control programmes.
    Int J Tuberc Lung Dis. 2020;24:1227-1228.
    PubMed    


  193. DE SOUZA CDF, Coutinho HS, Costa MM, Magalhaes MAFM, et al
    Impact of COVID-19 on TB diagnosis in Northeastern Brazil.
    Int J Tuberc Lung Dis. 2020;24:1220-1222.
    PubMed    


  194. ZHOU S, Van Staden Q, Toska E
    Resource reprioritisation amid competing health risks for TB and COVID-19.
    Int J Tuberc Lung Dis. 2020;24:1215-1216.
    PubMed    


  195. KADOTA JL, Reza TF, Nalugwa T, Kityamuwesi A, et al
    Impact of shelter-in-place on TB case notifications and mortality during the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2020;24:1212-1214.
    PubMed    


  196. HAAS MK, Ignatius EH, Stout JE, Dooley KE, et al
    Finding the right balance between efficacy and tolerability for TB treatment.
    Int J Tuberc Lung Dis. 2020;24:1225b-1226.
    PubMed    


  197. WANG EY, Ahluwalia IB, Mase SR
    Response to Correspondence: The impact of smoking on TB treatment outcomes includes recurrent TB.
    Int J Tuberc Lung Dis. 2020;24:1225a-1225.
    PubMed    


  198. DHAMGAYE TM
    In reply: Latent TB treatment in pregnant women: a patient perspective.
    Int J Tuberc Lung Dis. 2020;24:1226-1227.
    PubMed    


  199. CHIANG CY, Bam TS
    The impact of smoking on TB treatment outcomes includes recurrent TB.
    Int J Tuberc Lung Dis. 2020;24:1224-1225.
    PubMed    


    October 2020
  200. KIM HW, Min J, Shin AY, Koo HK, et al
    Reasons why patients with tuberculosis in South Korea stop anti-TB treatment: a cross-sectional study.
    Int J Tuberc Lung Dis. 2020;24:1016-1023.
    PubMed     Abstract available


  201. SHAHRIARIRAD R, Fallahi MJ
    TB and the COVID-19 pandemic: brothers in arms against lung health.
    Int J Tuberc Lung Dis. 2020;24:1126-1127.
    PubMed    


  202. WU Z, Chen J, Xia Z, Pan Q, et al
    Impact of the COVID-19 pandemic on the detection of TB in Shanghai, China.
    Int J Tuberc Lung Dis. 2020;24:1122-1124.
    PubMed    


  203. MENEGUIM AC, Rebello L, Das M, Ravi S, et al
    Adapting TB services during the COVID-19 pandemic in Mumbai, India.
    Int J Tuberc Lung Dis. 2020;24:1119-1121.
    PubMed    


  204. HELDAL E, Dlodlo RA
    Estimating subnational TB burden-why not strengthen and use routine recording and reporting?
    Int J Tuberc Lung Dis. 2020;24:1125-1127.
    PubMed    


  205. AKKERMAN OW, Tiberi S
    The importance of knowing why TB patients stop anti-TB treatment.
    Int J Tuberc Lung Dis. 2020;24:989-990.
    PubMed    


    September 2020
  206. YASSIN M, Grzemska M
    Response to 'The Green Light Committee could contribute to ending tuberculosis .
    Int J Tuberc Lung Dis. 2020;24:984.
    PubMed    


  207. NGUYEN TBP, Nguyen TA, Luu BK, Le TTO, et al
    A comparison of digital chest radiography and Xpert((R)) MTB/RIF in active case finding for tuberculosis.
    Int J Tuberc Lung Dis. 2020;24:934-940.
    PubMed     Abstract available


  208. CHIANG CH, Lee GH, Chiang TH, Tang PU, et al
    Disseminated Mycobacterium avium complex infection as a differential diagnosis of tuberculosis in HIV patients.
    Int J Tuberc Lung Dis. 2020;24:922-927.
    PubMed     Abstract available


  209. LOVEDAY M, Hlangu S, Furin J
    Breastfeeding in women living with tuberculosis.
    Int J Tuberc Lung Dis. 2020;24:880-891.
    PubMed     Abstract available


  210. ADEWOLE OO
    Impact of COVID-19 on TB care: experiences of a treatment centre in Nigeria.
    Int J Tuberc Lung Dis. 2020;24:981-982.
    PubMed    


  211. VAN DER WALT M, Keddy KH
    How COVID-19 can instruct TB research: ensuring the safety of researchers exposed to infectious disease.
    Int J Tuberc Lung Dis. 2020;24:978-980.
    PubMed    


  212. WILSON FA, Miller TL, Stimpson JP
    COVID-19 and TB control in immigrant communities.
    Int J Tuberc Lung Dis. 2020;24:975-977.
    PubMed    


  213. ECHEVERRIA G, Espinoza W, de Waard JH
    How TB and COVID-19 compare: an opportunity to integrate both control programmes.
    Int J Tuberc Lung Dis. 2020;24:971-974.
    PubMed    


  214. MULDER C, Nkiligi E, Kondo Z, Scholten JN, et al
    What to look for when using SUBsET for subnational TB incidence estimates.
    Int J Tuberc Lung Dis. 2020;24:983-984.
    PubMed    


  215. WANG J, Garcia-Basteiro AL
    Should vitamin D supplementation be used concomitantly with LTBI treatment?
    Int J Tuberc Lung Dis. 2020;24:875-876.
    PubMed    


    August 2020
  216. KOURA KG, Harries AD, Fujiwara PI, Dlodlo RA, et al
    COVID-19 in Africa: community and digital technologies for tuberculosis management.
    Int J Tuberc Lung Dis. 2020;24:863-865.
    PubMed    


  217. LOUIE JK, Reid M, Stella J, Agraz-Lara R, et al
    A decrease in tuberculosis evaluations and diagnoses during the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2020;24:860-862.
    PubMed    


  218. DEWI IMW, Soeroto AY, Putriyani G, Hanifah W, et al
    Aspergillus fumigatus-specific antibodies in patients with chronic tuberculosis.
    Int J Tuberc Lung Dis. 2020;24:853-856.
    PubMed    


  219. SILVA LL, Valverde TL, de Carvalho Dutra A, De Andrade L, et al
    Geospatial analysis and factors associated with poor outcome for multidrug-resistant tuberculosis.
    Int J Tuberc Lung Dis. 2020;24:844-846.
    PubMed    


  220. ALLWOOD BW, van der Zalm MM, Amaral AFS, Byrne A, et al
    Post-tuberculosis lung health: perspectives from the First International Symposium.
    Int J Tuberc Lung Dis. 2020;24:820-828.
    PubMed     Abstract available


  221. CHIMEH RA, Gafar F, Pradipta IS, Akkerman OW, et al
    Clinical and economic impact of medication non-adherence in drug-susceptible tuberculosis: a systematic review.
    Int J Tuberc Lung Dis. 2020;24:811-819.
    PubMed     Abstract available


  222. SIAPKA M, Vassall A, Cunnama L, Pineda C, et al
    Cost of tuberculosis treatment in low- and middle-income countries: systematic review and meta-regression.
    Int J Tuberc Lung Dis. 2020;24:802-810.
    PubMed     Abstract available


  223. HAN X, Chen X, Sha W, Zhang X, et al
    Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis in China.
    Int J Tuberc Lung Dis. 2020;24:789-794.
    PubMed     Abstract available


  224. MCARDLE AJ, Keane D, Seddon JA, Bernatoniene J, et al
    Vitamin D deficiency is associated with tuberculosis disease in British children.
    Int J Tuberc Lung Dis. 2020;24:782-788.
    PubMed     Abstract available


  225. VISCA D, Centis R, Munoz-Torrico M, Pontali E, et al
    Post-tuberculosis sequelae: the need to look beyond treatment outcome.
    Int J Tuberc Lung Dis. 2020;24:761-762.
    PubMed    


  226. ZUMLA A, Marais BJ, McHugh TD, Maeurer M, et al
    COVID-19 and tuberculosis-threats and opportunities.
    Int J Tuberc Lung Dis. 2020;24:757-760.
    PubMed    


  227. JAMAL WZ, Habib S, Khowaja S, Safdar N, et al
    COVID-19: ensuring continuity of TB services in the private sector.
    Int J Tuberc Lung Dis. 2020;24:870-872.
    PubMed    


  228. WATTS K, McKeown A, Denholm J, Baker AM, et al
    Responding to COVID-19: adjusting TB services in a low-burden setting.
    Int J Tuberc Lung Dis. 2020;24:866-869.
    PubMed    


  229. CHIANG CY
    Green Light Committee and WHO recommendations.
    Int J Tuberc Lung Dis. 2020;24:873-874.
    PubMed    


    July 2020
  230. KUBIAK RW, Drain PK, Hochberg NS
    How should body mass index inform active tuberculosis screening in diabetes clinics in Asia?
    Int J Tuberc Lung Dis. 2020;24:753.
    PubMed    


  231. LIU C, Yu Y, Fleming J, Wang T, et al
    Severe COVID-19 cases with a history of active or latent tuberculosis.
    Int J Tuberc Lung Dis. 2020;24:747-749.
    PubMed    


  232. BURZYNSKI J, Macaraig M, Nilsen D, Schluger NW, et al
    Transforming essential services for tuberculosis during the COVID-19 pandemic: lessons from New York City.
    Int J Tuberc Lung Dis. 2020;24:735-736.
    PubMed    


  233. KADOTA JL, Katamba A, Musinguzi A, Welishe F, et al
    Willingness to accept reimbursement for visits to an HIV clinic for tuberculosis preventive therapy.
    Int J Tuberc Lung Dis. 2020;24:729-731.
    PubMed    


  234. CHIANG SS, Beckhorn CB, Wong M, Lecca L, et al
    Patterns of suboptimal adherence among adolescents treated for tuberculosis.
    Int J Tuberc Lung Dis. 2020;24:723-725.
    PubMed    


  235. VISCA D, Centis R, D'Ambrosio L, Munoz-Torrico M, et al
    The need for pulmonary rehabilitation following tuberculosis treatment.
    Int J Tuberc Lung Dis. 2020;24:720-722.
    PubMed    


  236. EDWARDS T, White LV, Lee N, Castro MC, et al
    Effects of comorbidities on quality of life in Filipino people with tuberculosis.
    Int J Tuberc Lung Dis. 2020;24:712-719.
    PubMed     Abstract available


  237. IQBAL SA, Isenhour CJ, Mazurek G, Truman BI, et al
    Diagnostic code agreement for electronic health records and claims data for tuberculosis.
    Int J Tuberc Lung Dis. 2020;24:706-711.
    PubMed     Abstract available


  238. MUNOZ-TORRICO M, Cid-Juarez S, Gochicoa-Rangel L, Torre-Bouscolet L, et al
    Functional impact of sequelae in drug-susceptible and multidrug-resistant tuberculosis.
    Int J Tuberc Lung Dis. 2020;24:700-705.
    PubMed     Abstract available


  239. WATTHANANUKUL T, Liabsuetrakul T, Pungrassami P, Chongsuvivatwong V, et al
    Effect of Global Fund financial support for patients with multidrug-resistant tuberculosis.
    Int J Tuberc Lung Dis. 2020;24:686-693.
    PubMed     Abstract available


  240. RICKMAN HM, Cohn S, Lala SG, Waja Z, et al
    Subclinical tuberculosis and adverse infant outcomes in pregnant women with HIV.
    Int J Tuberc Lung Dis. 2020;24:681-685.
    PubMed     Abstract available


  241. MADHANI F, Maniar RA, Burfat A, Ahmed M, et al
    Automated chest radiography and mass systematic screening for tuberculosis.
    Int J Tuberc Lung Dis. 2020;24:665-673.
    PubMed     Abstract available


  242. BASHAM CA, Grewal N, Orr PH, McMullin K, et al
    What will it take to achieve meaningful action on tuberculosis among Indigenous Peoples?
    Int J Tuberc Lung Dis. 2020;24:661-664.
    PubMed    


  243. ROSSATO SILVA D, van den Hof S
    Use of insurance claims and electronic health records to assess tuberculosis and latent tuberculosis diagnosis.
    Int J Tuberc Lung Dis. 2020;24:659-660.
    PubMed    


  244. TADYANEMHANDU C, Chirenda J, Garvey C, Metcalfe J, et al
    Treatment success, but living with the consequences of post-tuberculosis sequelae.
    Int J Tuberc Lung Dis. 2020;24:657-658.
    PubMed    


  245. SCHAAF HS, du Preez K, Kruger M, Solomons R, et al
    Bacille Calmette-Guerin (BCG) vaccine and the COVID-19 pandemic: responsible stewardship is needed.
    Int J Tuberc Lung Dis. 2020;24:732-734.
    PubMed    


    June 2020
  246. DE SOUZA JVP, Murase LS, Caleffi-Ferracioli KR, Palomo CT, et al
    Isoniazid and verapamil modulatory activity and efflux pump gene expression in Mycobacterium tuberculosis.
    Int J Tuberc Lung Dis. 2020;24:591-596.
    PubMed     Abstract available


  247. GUPTA A, Singla R, Caminero JA, Singla N, et al
    Impact of COVID-19 on tuberculosis services in India.
    Int J Tuberc Lung Dis. 2020;24:637-639.
    PubMed    


  248. SANDY C, Takarinda KC, Timire C, Mutunzi H, et al
    Preparing national tuberculosis control programmes for COVID-19.
    Int J Tuberc Lung Dis. 2020;24:634-636.
    PubMed    


  249. PROOPS DC, Knorr JA, Meissner JS, Kreiswirth BN, et al
    Epidemiology of tuberculosis among healthcare personnel in New York City.
    Int J Tuberc Lung Dis. 2020;24:619-625.
    PubMed     Abstract available


  250. COCOZZA AM, Linh NN, Jaramillo E
    Is effective patient support missing in the global response to multidrug-resistant tuberculosis?
    Int J Tuberc Lung Dis. 2020;24:626-630.
    PubMed     Abstract available


  251. ONGOLE JJ, Rossouw TM, Fourie PB, Stoltz AC, et al
    Sustaining essential healthcare in Africa during the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2020;24:643-645.
    PubMed    


  252. VAN CREVEL R, Andia-Biraro I, Ntinginya NE, Chamba N, et al
    Response to IJTLD article, "Having diabetes and being underweight in Asia: a potent risk factor for tuberculosis".
    Int J Tuberc Lung Dis. 2020;24:632-633.
    PubMed    


  253. NAMKOONG H, Horita N, Ebina-Shibuya R
    Concern over a COVID-19-related BCG shortage.
    Int J Tuberc Lung Dis. 2020;24:642-643.
    PubMed    


  254. MORAN A, Kula N, Jagwer G, Broughton E, et al
    Examining the cost of community-based tuberculosis treatment in South Africa.
    Int J Tuberc Lung Dis. 2020;24:612-618.
    PubMed     Abstract available


  255. LAZARUS JV
    Correspondence on: "Should we consider a 'fourth 90' for tuberculosis?"
    Int J Tuberc Lung Dis. 2020;24:631-632.
    PubMed    


  256. HARRIES AD
    In Response to Reinout van Crevel et al.
    Int J Tuberc Lung Dis. 2020;24:634.
    PubMed    


    May 2020
  257. PANG Y, Liu Y, Du J, Gao J, et al
    Impact of COVID-19 on tuberculosis control in China.
    Int J Tuberc Lung Dis. 2020;24:545-547.
    PubMed    


  258. DARA M, Sotgiu G, Reichler MR, Chiang CY, et al
    New diseases and old threats: lessons from tuberculosis for the COVID-19 response.
    Int J Tuberc Lung Dis. 2020;24:544-545.
    PubMed    


  259. PONTALI E, Tiberi S
    Green Light Committee and drug-resistant-tuberculosis: how to address the new challenges?
    Int J Tuberc Lung Dis. 2020;24:539.
    PubMed    


  260. HENG M, Allmendinger S, Chiang CY, Trebucq A, et al
    Progress in the roll-out of multidrug-resistant tuberculosis (MDR-TB) treatments.
    Int J Tuberc Lung Dis. 2020;24:535-536.
    PubMed    


  261. MONDONI M, Sotgiu G
    Endobronchial ultrasound-guided transbronchial needle aspiration and tuberculosis mediastinal lymphadenopathy.
    Int J Tuberc Lung Dis. 2020;24:534.
    PubMed    


  262. ARINAMINPATHY N, Chin DP, Sachdeva KS, Rao R, et al
    Modelling the potential impact of adherence technologies on tuberculosis in India.
    Int J Tuberc Lung Dis. 2020;24:526-533.
    PubMed     Abstract available


  263. GARFEIN RS, Liu L, Cuevas-Mota J, Collins K, et al
    Evaluation of recorded video-observed therapy for anti-tuberculosis treatment.
    Int J Tuberc Lung Dis. 2020;24:520-525.
    PubMed     Abstract available


  264. KAWATSU L, Uchimura K, Ohkado A
    A cost-effectiveness study of tuberculosis and latent tuberculosis infection screening in prisons in Japan.
    Int J Tuberc Lung Dis. 2020;24:506-511.
    PubMed     Abstract available


  265. MAUG AKJ, Hossain MA, Gumusboga M, Decroo T, et al
    First-line tuberculosis treatment with double-dose rifampicin is well tolerated.
    Int J Tuberc Lung Dis. 2020;24:499-505.
    PubMed     Abstract available


  266. PARK SC, Kang MJ, Han CH, Lee SM, et al
    Long-term mortality of patients with tuberculosis in Korea.
    Int J Tuberc Lung Dis. 2020;24:492-498.
    PubMed     Abstract available


  267. BUTOV D, Lange C, Heyckendorf J, Kalmykova I, et al
    Multidrug-resistant tuberculosis in the Kharkiv Region, Ukraine.
    Int J Tuberc Lung Dis. 2020;24:485-491.
    PubMed     Abstract available


  268. ANDREWS JR, Cobelens F, Horsburgh CR, Hatherill M, et al
    Seasonal drivers of tuberculosis: evidence from over 100 years of notifications in Cape Town.
    Int J Tuberc Lung Dis. 2020;24:477-484.
    PubMed     Abstract available


  269. DENHOLM J
    Seasonality, climate change and tuberculosis: new data and old lessons.
    Int J Tuberc Lung Dis. 2020;24:469.
    PubMed    


  270. COX V, Wilkinson L, Grimsrud A, Hughes J, et al
    Critical changes to services for TB patients during the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2020;24:542-544.
    PubMed    


  271. ELGER BS, Mirzayev F, Afandiyev S, Gurbanova E, et al
    Ethical issues in tuberculosis screening and the use of new drugs for prisoners.
    Int J Tuberc Lung Dis. 2020;24:57-60.
    PubMed     Abstract available


  272. HERMANNS S, Bhan A, Viney K
    Ethics and benefits of systematic screening for active tuberculosis.
    Int J Tuberc Lung Dis. 2020;24:44-47.
    PubMed     Abstract available


  273. HUMMEL P, Ahamed N, Amanullah F
    Ethical issues surrounding childhood tuberculosis.
    Int J Tuberc Lung Dis. 2020;24:27-31.
    PubMed     Abstract available


  274. DENHOLM JT, Millan-Marcelo JC, Fiekert K
    Latent tuberculosis infection and the EndTB Strategy: ethical tensions and imperatives.
    Int J Tuberc Lung Dis. 2020;24:21-26.
    PubMed     Abstract available


  275. BAYER R, Fairchild AL, Zignol M, Castro KG, et al
    Tuberculosis surveillance and its discontents: the ethical paradox.
    Int J Tuberc Lung Dis. 2020;24:9-14.
    PubMed     Abstract available


  276. HARDING R, Snyman L, Ostgathe C, Odell S, et al
    The ethical imperative to relieve suffering for people with tuberculosis by ensuring access to palliative care.
    Int J Tuberc Lung Dis. 2020;24:3-8.
    PubMed     Abstract available


  277. FURIN J
    Can Green Light Committees help "end TB"?
    Int J Tuberc Lung Dis. 2020;24:540.
    PubMed    


    April 2020
  278. KAPUR A
    Randomised clinical trials for tuberculosis prophylaxis in people with diabetes mellitus.
    Int J Tuberc Lung Dis. 2020;24:465-466.
    PubMed    


  279. SHEDRAWY J, Jansson L, Bruchfeld J, Lonnroth K, et al
    Health-related quality of life among persons treated for tuberculosis in a European setting.
    Int J Tuberc Lung Dis. 2020;24:461-463.
    PubMed    


  280. SCHWOEBEL V, Koura KG, Adjobimey M, Gnanou S, et al
    Tuberculosis contact investigation and short-course preventive therapy among young children in Africa.
    Int J Tuberc Lung Dis. 2020;24:452-460.
    PubMed     Abstract available


  281. YOUNG C, Barker S, Ehrlich R, Kistnasamy B, et al
    Computer-aided detection for tuberculosis and silicosis in chest radiographs of gold miners of South Africa.
    Int J Tuberc Lung Dis. 2020;24:444-451.
    PubMed     Abstract available


  282. MIKIASHVILI L, Kipiani M, Schechter MC, Avaliani Z, et al
    Linezolid use for drug-resistant tuberculosis in Georgia: a retrospective cohort study.
    Int J Tuberc Lung Dis. 2020;24:436-443.
    PubMed     Abstract available


  283. PIERRE-AUDIGIER C, Talla C, Alame-Emane AK, Audigier B, et al
    Tuberculosis trends in a hot-spot region in Paris, France.
    Int J Tuberc Lung Dis. 2020;24:428-435.
    PubMed     Abstract available


  284. TOMENY EM, Mendoza VL, Marcelo DB, Barrameda AJD, et al
    Patient-cost survey for tuberculosis in the context of patient-pathway modelling.
    Int J Tuberc Lung Dis. 2020;24:420-427.
    PubMed     Abstract available


  285. O'SON L, Hulland E, Cookson ST, Castro KG, et al
    Epidemiology and risk factors for extrapulmonary tuberculosis in Lebanon.
    Int J Tuberc Lung Dis. 2020;24:414-419.
    PubMed     Abstract available


  286. GOBAUD AN, Haley CA, Wilson JW, Bhavaraju R, et al
    Multidrug-resistant tuberculosis care in the United States.
    Int J Tuberc Lung Dis. 2020;24:409-413.
    PubMed     Abstract available


  287. MCCREESH N, Grant AD, Yates TA, Karat AS, et al
    Tuberculosis from transmission in clinics in high HIV settings may be far higher than contact data suggest.
    Int J Tuberc Lung Dis. 2020;24:403-408.
    PubMed     Abstract available


  288. KIM HY, Hanrahan CF, Dowdy DW, Martinson NA, et al
    Priorities among HIV-positive individuals for tuberculosis preventive therapies.
    Int J Tuberc Lung Dis. 2020;24:396-402.
    PubMed     Abstract available


  289. MASUKU SD, Berhanu R, Van Rensburg C, Ndjeka N, et al
    Managing multidrug-resistant tuberculosis in South Africa: a budget impact analysis.
    Int J Tuberc Lung Dis. 2020;24:376-382.
    PubMed     Abstract available


  290. MILLER CR, Mitchell EMH, Nishikiori N, Zwerling A, et al
    ScreenTB: a tool for prioritising risk groups and selecting algorithms for screening for active tuberculosis.
    Int J Tuberc Lung Dis. 2020;24:367-375.
    PubMed     Abstract available


  291. LANEY AS, Pontali E
    Computer-assisted interpretation of chest radiographs: signs of hope for silicosis and tuberculosis.
    Int J Tuberc Lung Dis. 2020;24:362-363.
    PubMed    


  292. CRUZ AT, Schwartzman K, Kitai I
    Fighting a hidden epidemic: expanding tuberculosis preventive treatment to the youngest household contacts.
    Int J Tuberc Lung Dis. 2020;24:357-359.
    PubMed    


  293. BASHAM CA, Romanowski K, Johnston JC
    Cardiovascular disease: the forgotten cousin of post-TB health?
    Int J Tuberc Lung Dis. 2020;24:466-467.
    PubMed    


    March 2020
  294. HASKER E, Assoumani Y, Mzembaba A, Zakir AM, et al
    Using a geographic information system as a management tool for tuberculosis control.
    Int J Tuberc Lung Dis. 2020;24:354-356.
    PubMed    


  295. YATES TA, Tomlinson LA, Douglas IJ
    Proton pump inhibitors and tuberculosis risk.
    Int J Tuberc Lung Dis. 2020;24:353-354.
    PubMed    


  296. KOHLENBERG A, Kodmon C, van den Boom M, van der Werf MJ, et al
    Tuberculosis surveillance in adolescents: what to learn from European Union/European Economic Area data?
    Int J Tuberc Lung Dis. 2020;24:347-352.
    PubMed     Abstract available


  297. GUNASEKERA K, Cohen T, Gao W, Ayles H, et al
    Smoking and HIV associated with subclinical tuberculosis: analysis of a population-based prevalence survey.
    Int J Tuberc Lung Dis. 2020;24:340-346.
    PubMed     Abstract available


  298. NGABONZIZA JS, Habimana YM, Decroo T, Migambi P, et al
    Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in Rwanda.
    Int J Tuberc Lung Dis. 2020;24:329-339.
    PubMed     Abstract available


  299. BONSU F, Addo KK, Alebachew Z, Gyapong J, et al
    National population-based tuberculosis prevalence survey in Ghana, 2013.
    Int J Tuberc Lung Dis. 2020;24:321-328.
    PubMed     Abstract available


  300. JANSSON L, Shedrawy J, Lonnroth K, Bruchfeld J, et al
    Latent tuberculosis in pregnant women: a patient perspective.
    Int J Tuberc Lung Dis. 2020;24:310-315.
    PubMed     Abstract available


  301. LOPEZ-MEDINA EM, Sainz T, de Ory SJ, Mellado-Pena MJ, et al
    Tuberculosis in a Spanish cohort of children living with HIV: the CHOTIS study (Childhood HIV & TB study).
    Int J Tuberc Lung Dis. 2020;24:303-309.
    PubMed     Abstract available


  302. WANG M, Liu F, Li Q, Yin Q, et al
    Quality assessment of guidelines for the management of Mycobacterium tuberculosis infection in children.
    Int J Tuberc Lung Dis. 2020;24:287-294.
    PubMed     Abstract available


  303. ARNEDO-PENA A, Juan-Cerdan JV, Romeu-Garcia M, Sorribes-Segura S, et al
    Vitamin D status and latent tuberculosis infection: conversion in nursing homes, Spain.
    Int J Tuberc Lung Dis. 2020;24:278-286.
    PubMed     Abstract available


  304. REICHLER MR, Hirsch-Moverman Y
    Antenatal diagnosis of latent tuberculosis infection and post-partum treatment: patient perspectives.
    Int J Tuberc Lung Dis. 2020;24:266-267.
    PubMed    


  305. DEDICOAT M
    Where next with for vitamin D and tuberculosis?
    Int J Tuberc Lung Dis. 2020;24:265.
    PubMed    


  306. DOWDY DW
    The urgent need to improve clinical practice guidelines for pediatric tuberculosis.
    Int J Tuberc Lung Dis. 2020;24:264.
    PubMed    


    February 2020
  307. SINGH AR, Shewade HD, Pandey R
    Near real-time supervision of home visits for patients with tuberculosis.
    Int J Tuberc Lung Dis. 2020;24:260-261.
    PubMed    


  308. TALBOT EA
    Response to Dr Granich's letter regarding 'Tackling drug-resistant tuberculosis: we need a critical synergy of product and process innovations'.
    Int J Tuberc Lung Dis. 2020;24:259.
    PubMed    


  309. PARWATI CG, Farid MN, Nasution HS, Basri C, et al
    Estimation of subnational tuberculosis burden: generation and application of a new tool in Indonesia.
    Int J Tuberc Lung Dis. 2020;24:250-257.
    PubMed     Abstract available


  310. PARK S, Jo KW, Shim TS
    Treatment outcomes in multidrug-resistant tuberculosis according to pyrazinamide susceptibility.
    Int J Tuberc Lung Dis. 2020;24:233-239.
    PubMed     Abstract available


  311. QUISPE N, Asencios L, Obregon C, Velasquez GE, et al
    The fourth national anti-tuberculosis drug resistance survey in Peru.
    Int J Tuberc Lung Dis. 2020;24:207-213.
    PubMed     Abstract available


  312. GATTI A, Ceriani C, De Paschale M, Magnani C, et al
    Quantification of neutrophil and monocyte CD64 expression: a predictive biomarker for active tuberculosis.
    Int J Tuberc Lung Dis. 2020;24:196-201.
    PubMed     Abstract available


  313. WANG EY, Arrazola RA, Mathema B, Ahluwalia IB, et al
    The impact of smoking on tuberculosis treatment outcomes: a meta-analysis.
    Int J Tuberc Lung Dis. 2020;24:170-175.
    PubMed     Abstract available


  314. RABKIN M, Howard AA, Ehrenkranz P, Fernandez LG, et al
    Leveraging differentiated HIV service delivery to expand tuberculosis preventive treatment: a call to action.
    Int J Tuberc Lung Dis. 2020;24:165-169.
    PubMed     Abstract available


  315. GRANICH R
    Time for hand wringing about TB diagnostics is over: show us the money and the impact.
    Int J Tuberc Lung Dis. 2020;24:258-259.
    PubMed    


    January 2020
  316. WU MY, Shu CC, Lin HH
    Authors reply to letter to the Editor "Chronic kidney disease, tuberculosis and climate change".
    Int J Tuberc Lung Dis. 2020;24:133-134.
    PubMed    


  317. HARRIES AD
    Chronic kidney disease, tuberculosis and climate change.
    Int J Tuberc Lung Dis. 2020;24:132-133.
    PubMed    


  318. LEROLLE N, Laanani M, Galicier L, Riviere S, et al
    Factors associated with tuberculosis-associated haemophagocytic syndrome: a multicentre case-control study.
    Int J Tuberc Lung Dis. 2020;24:124-130.
    PubMed     Abstract available


  319. LINH NN, Wares F, Cocozza AM, Uplekar M, et al
    No universal access to drug-resistant tuberculosis care without engaging all health care providers.
    Int J Tuberc Lung Dis. 2020;24:118-123.
    PubMed     Abstract available


  320. DESHMUKH S, Atre S, Chavan A, Raskar S, et al
    Assessment of the Xpert assay among adult pulmonary tuberculosis suspects with and without diabetes mellitus.
    Int J Tuberc Lung Dis. 2020;24:113-117.
    PubMed     Abstract available


  321. BARSS L, Moayedi-Nia S, Campbell JR, Oxlade O, et al
    Interventions to reduce losses in the cascade of care for latent tuberculosis: a systematic review and meta-analysis.
    Int J Tuberc Lung Dis. 2020;24:100-109.
    PubMed     Abstract available


  322. CHEN MP, Miramontes R, Kammerer JS
    Multidrug-resistant tuberculosis in the United States, 2011-2016: patient characteristics and risk factors.
    Int J Tuberc Lung Dis. 2020;24:92-99.
    PubMed     Abstract available


  323. HILL J, Dickson-Hall L, Grant AD, Grundy C, et al
    Drug-resistant tuberculosis patient care journeys in South Africa: a pilot study using routine laboratory data.
    Int J Tuberc Lung Dis. 2020;24:83-91.
    PubMed     Abstract available


  324. RAGAN EJ, Kleinman MB, Sweigart B, Gnatienko N, et al
    The impact of alcohol use on tuberculosis treatment outcomes: a systematic review and meta-analysis.
    Int J Tuberc Lung Dis. 2020;24:73-82.
    PubMed     Abstract available


  325. HONG H, Dowdy DW, Dooley KE, Francis HW, et al
    Risk of hearing loss among multidrug-resistant tuberculosis patients according to cumulative aminoglycoside dose.
    Int J Tuberc Lung Dis. 2020;24:65-72.
    PubMed     Abstract available


  326. PERUMAL R, Naidoo K, Naidoo A, Ramachandran G, et al
    A systematic review and meta-analysis of first-line tuberculosis drug concentrations and treatment outcomes.
    Int J Tuberc Lung Dis. 2020;24:48-64.
    PubMed     Abstract available


  327. COCOZZA AM, Linh NN, Nathavitharana RR, Ahmad U, et al
    An assessment of current tuberculosis patient care and support policies in high-burden countries.
    Int J Tuberc Lung Dis. 2020;24:36-42.
    PubMed     Abstract available


  328. REEVES H, Grandjean Lapierre S, Razafindrina K, Andriamiadanarivo A, et al
    Evaluating the use of educational videos to support the tuberculosis care cascade in remote Madagascar.
    Int J Tuberc Lung Dis. 2020;24:28-35.
    PubMed     Abstract available


  329. GUTIERREZ C, Somoskovi A
    Serum levels of tuberculosis drugs-beyond the quantitative data.
    Int J Tuberc Lung Dis. 2020;24:6-7.
    PubMed    


  330. CHAULK CP, Moonan PK
    Over the limit: tuberculosis and excessive alcohol use.
    Int J Tuberc Lung Dis. 2020;24:3-4.
    PubMed    


    December 2019
  331. DENHOLM JT, Leontiou C, McKeown A, Watts KN, et al
    Speaking up: language services, tuberculosis and human rights.
    Int J Tuberc Lung Dis. 2019;23:1336.
    PubMed    


  332. MEKONNEN D, Derbie A, Abeje A, Shumet A, et al
    Genomic diversity and transmission dynamics of M. tuberculosis in Africa: a systematic review and meta-analysis.
    Int J Tuberc Lung Dis. 2019;23:1314-1326.
    PubMed     Abstract available


  333. SURIE D, Interrante JD, Pathmanathan I, Patel MR, et al
    Policies, practices and barriers to implementing tuberculosis preventive treatment-35 countries, 2017.
    Int J Tuberc Lung Dis. 2019;23:1308-1313.
    PubMed     Abstract available


  334. LIFAN Z, Sainan B, Feng S, Siyan Z, et al
    Linezolid for the treatment of extensively drug-resistant tuberculosis: a systematic review and meta-analysis.
    Int J Tuberc Lung Dis. 2019;23:1293-1307.
    PubMed     Abstract available


  335. HANDEL A, Martinez L, Sekandi JN, Bellan SE, et al
    Evidence for supercoughers in an analysis of six tuberculosis cohorts from China, Peru, The Gambia and Uganda.
    Int J Tuberc Lung Dis. 2019;23:1286-1292.
    PubMed     Abstract available


  336. ZMAK L, Obrovac M, Makek MJ, Perko G, et al
    From Peruvian mummies to living humans: first case of pulmonary tuberculosis caused by Mycobacterium pinnipedii.
    Int J Tuberc Lung Dis. 2019;23:1283-1285.
    PubMed     Abstract available


  337. SOH AZ, Chee CBE, Wang YT, Yuan JM, et al
    Diabetes and body mass index in relation to risk of active tuberculosis: a prospective population-based cohort.
    Int J Tuberc Lung Dis. 2019;23:1277-1282.
    PubMed     Abstract available


  338. PENG Y, Zhu Y, Ao G, Chen Z, et al
    Effect of bronchial artery embolisation on the management of tuberculosis-related haemoptysis.
    Int J Tuberc Lung Dis. 2019;23:1269-1276.
    PubMed     Abstract available


  339. WADEMAN DT, Busakwe L, Nicholson TJ, van der Zalm M, et al
    Acceptability of a first-line anti-tuberculosis formulation for children: qualitative data from the SHINE trial.
    Int J Tuberc Lung Dis. 2019;23:1263-1268.
    PubMed     Abstract available


  340. CHANDAK RJ, Malhotra B, Bhargava S, Goel SK, et al
    Evaluation of MTBDRsl for detecting resistance in Mycobacterium tuberculosis to second-line drugs.
    Int J Tuberc Lung Dis. 2019;23:1257-1262.
    PubMed     Abstract available


  341. DUNSTAN SJ, Williamson DA, Denholm JT
    Understanding the global tuberculosis epidemic: moving towards routine whole-genome sequencing.
    Int J Tuberc Lung Dis. 2019;23:1241-1242.
    PubMed    


  342. HARRIES AD
    Having diabetes and being underweight in Asia: a potent risk factor for tuberculosis.
    Int J Tuberc Lung Dis. 2019;23:1237-1238.
    PubMed    


  343. SUDBURY E, Villanueva P, Goetzinger F, Tebruegge M, et al
    The impact of bacille Calmette-Guerin vaccination on tuberculin skin test results in young children.
    Int J Tuberc Lung Dis. 2019;23:1335-1336.
    PubMed    


    November 2019
  344. HARRIES AD, Dlodlo RA, Brigden G, Mortimer K, et al
    Should we consider a 'fourth 90' for tuberculosis?
    Int J Tuberc Lung Dis. 2019 Nov 21. doi: 10.5588/ijtld.19.0471.
    PubMed     Abstract available


  345. TIMIRE C, Sandy C, Harries AD
    Eliminating tuberculosis by 2035: tackling the financial barriers at all stages of the cascade of care.
    Int J Tuberc Lung Dis. 2019;23:1235.
    PubMed    


  346. COIT J, Mendoza M, Pinedo C, Marin H, et al
    Performance of a household tuberculosis exposure survey among children in a Latin American setting.
    Int J Tuberc Lung Dis. 2019;23:1223-1227.
    PubMed     Abstract available


  347. RIVERA VR, Lu L, Ocheretina O, Jean Juste MA, et al
    Diagnostic yield of active case finding for tuberculosis at human immunodeficiency virus testing in Haiti.
    Int J Tuberc Lung Dis. 2019;23:1217-1222.
    PubMed     Abstract available


  348. SUMALANI KK, Akhter N, Chawla D, Rizvi NA, et al
    Diagnostic yield of sputum induction in patients with pleural tuberculosis at a tertiary care hospital in Karachi.
    Int J Tuberc Lung Dis. 2019;23:1213-1216.
    PubMed     Abstract available


  349. ERLINGER S, Stracker N, Hanrahan C, Nonyane S, et al
    Tuberculosis patients with higher levels of poverty face equal or greater costs of illness.
    Int J Tuberc Lung Dis. 2019;23:1205-1212.
    PubMed     Abstract available


  350. JORDAN AM, Podewils LJ, Castro KG, Zishiri V, et al
    Prevalence and risk factors of tuberculosis disease in South African correctional facilities in 2015.
    Int J Tuberc Lung Dis. 2019;23:1198-1204.
    PubMed     Abstract available


  351. VINEY K, Amaral S, Marques EB, Siroka A, et al
    Four of five tuberculosis patients experience catastrophic costs related to TB diagnosis and care in Timor-Leste.
    Int J Tuberc Lung Dis. 2019;23:1191-1197.
    PubMed     Abstract available


  352. AUGUSTE P, Madan J, Tsertsvadze A, Court R, et al
    Identifying latent tuberculosis in high-risk populations: systematic review and meta-analysis of test accuracy.
    Int J Tuberc Lung Dis. 2019;23:1178-1190.
    PubMed     Abstract available


  353. CADMUS S, Akinseye VO, van Soolingen D
    Mycobacterium bovis in humans and M. tuberculosis in animals in Nigeria: an overview from 1975-2014.
    Int J Tuberc Lung Dis. 2019;23:1162-1170.
    PubMed     Abstract available


  354. SCHULMAN H, Niward K, Abate E, Idh J, et al
    Sedimentation rate and suPAR in relation to disease activity and mortality in patients with tuberculosis.
    Int J Tuberc Lung Dis. 2019;23:1155-1161.
    PubMed     Abstract available


  355. LAM CK, Fluegge K, Macaraig M, Burzynski J, et al
    Cost savings associated with video directly observed therapy for treatment of tuberculosis.
    Int J Tuberc Lung Dis. 2019;23:1149-1154.
    PubMed     Abstract available


  356. BOCCIA D, Bond V
    The catastrophic cost of tuberculosis: advancing research and solutions.
    Int J Tuberc Lung Dis. 2019;23:1129-1130.
    PubMed    


  357. SCHON T
    The evaluation of routine immunological tests to estimate the risk of progression into active tuberculosis.
    Int J Tuberc Lung Dis. 2019;23:1127-1128.
    PubMed    


  358. PEDRAZZOLI D, Houben R, Viney K, Lonnroth K, et al
    Beyond measurement: taking bold multisector actions towards zero catastrophic costs and suffering due to TB.
    Int J Tuberc Lung Dis. 2019;23:1236.
    PubMed    


    October 2019
  359. FIOGBE AA, Agodokpessi G, Marcy O
    In reply to: Programmatic implementation of screening and management of pulmonary impairment post-tuberculosis in resource-limited countries: challenges and feasibility.
    Int J Tuberc Lung Dis. 2019;23:1123.
    PubMed    


  360. OLIVEIRA MCB, Sant'Anna CC, Luiz RR, Soares ECC, et al
    Contribution of Xpert MTB/RIF to clinical diagnosis in adolescents with tuberculosis in Rio de Janeiro, Brazil.
    Int J Tuberc Lung Dis. 2019;23:1115-1121.
    PubMed     Abstract available


  361. CAMELIQUE O, Scholtissen S, Dousset JP, Bonnet M, et al
    Mobile community-based active case-finding for tuberculosis among older populations in rural Cambodia.
    Int J Tuberc Lung Dis. 2019;23:1107-1114.
    PubMed     Abstract available


  362. VALVI C, Chandanwale A, Khadse S, Kulkarni R, et al
    Delays and barriers to early treatment initiation for childhood tuberculosis in India.
    Int J Tuberc Lung Dis. 2019;23:1090-1099.
    PubMed     Abstract available


  363. BHERING M, Kritski A, Nunes C, Duarte R, et al
    Multidrug-resistant tuberculosis in Lisbon: unfavourable treatment and associated factors, 2000-2014.
    Int J Tuberc Lung Dis. 2019;23:1075-1081.
    PubMed     Abstract available


  364. COURT R, Chirehwa MT, Wiesner L, de Vries N, et al
    Effect of tablet crushing on drug exposure in the treatment of multidrug-resistant tuberculosis.
    Int J Tuberc Lung Dis. 2019;23:1068-1074.
    PubMed     Abstract available


  365. BASTARD M, Sanchez-Padilla E, Hayrapetyan A, Kimenye K, et al
    What is the best culture conversion prognostic marker for patients treated for multidrug-resistant tuberculosis?
    Int J Tuberc Lung Dis. 2019;23:1060-1067.
    PubMed     Abstract available


  366. VINEY K, Mills T, Harley D
    Tuberculosis and diabetes mellitus: a dose-response relationship between the odds of tuberculosis and HbA1c.
    Int J Tuberc Lung Dis. 2019;23:1055-1059.
    PubMed     Abstract available


  367. GUGLIELMETTI L, Jaffre J, Bernard C, Brossier F, et al
    Multidisciplinary advisory teams to manage multidrug-resistant tuberculosis: the example of the French Consilium.
    Int J Tuberc Lung Dis. 2019;23:1050-1054.
    PubMed     Abstract available


  368. PONTALI E, Tadolini M, Migliori GB
    TB consilia and quality of tuberculosis management.
    Int J Tuberc Lung Dis. 2019;23:1048-1049.
    PubMed    


  369. DOWDY DW
    Implementation of Xpert((R)) MTB/RIF: real challenges, real promise.
    Int J Tuberc Lung Dis. 2019;23:1123.
    PubMed    


  370. TADYANEMHANDU C, Garvey C, Chin A, Metcalfe J, et al
    More should be done now for patients with TB-associated chronic lung disease.
    Int J Tuberc Lung Dis. 2019;23:1122-1123.
    PubMed    


  371. JINDAL SK
    Searching for a mole in the hill.
    Int J Tuberc Lung Dis. 2019;23:1047.
    PubMed    


    September 2019
  372. VANINO E, Tadolini M, Attard L, Cascavilla A, et al
    A multidrug resistant tuberculosis case treated with continuous infusion of meropenem in outpatient care.
    Int J Tuberc Lung Dis. 2019;23:1042.
    PubMed    


  373. GALEGO MA, Santos JV, Viana J, Freitas A, et al
    To be or not to be hospitalised with tuberculosis in Portugal.
    Int J Tuberc Lung Dis. 2019;23:1029-1034.
    PubMed     Abstract available


  374. DI BELLA S, Siroka A, Antonello RM, Zignol M, et al
    Tuberculosis screening in outpatient healthcare workers: lessons from a high-income, low TB burden country.
    Int J Tuberc Lung Dis. 2019;23:1024-1028.
    PubMed     Abstract available


  375. HUGHES J, Reuter A, Chabalala B, Isaakidis P, et al
    Adverse events among people on delamanid for rifampicin-resistant tuberculosis in a high HIV prevalence setting.
    Int J Tuberc Lung Dis. 2019;23:1017-1023.
    PubMed     Abstract available


  376. PEREA-JACOBO R, Muniz-Salazar R, Laniado-Laborin R, Cabello-Pasini A, et al
    Rifampin pharmacokinetics in tuberculosis-diabetes mellitus patients: a pilot study from Baja California, Mexico.
    Int J Tuberc Lung Dis. 2019;23:1012-1016.
    PubMed     Abstract available


  377. BUZIASHVILI M, Mirtskhulava V, Kipiani M, Blumberg HM, et al
    Rates and risk factors for nephrotoxicity and ototoxicity among tuberculosis patients in Tbilisi, Georgia.
    Int J Tuberc Lung Dis. 2019;23:1005-1011.
    PubMed     Abstract available


  378. OTA M, Uchimura K
    Trends of tuberculosis rates before and after the declaration as a public health emergency in Japan, 1992-2006.
    Int J Tuberc Lung Dis. 2019;23:1000-1004.
    PubMed     Abstract available


  379. HELD K, McAnaw S, Chiang CY, Trebucq A, et al
    Progress in global rollout of new multidrug-resistant tuberculosis treatments.
    Int J Tuberc Lung Dis. 2019;23:996-999.
    PubMed     Abstract available


  380. ZHANG HC, Ruan QL, Wu J, Zhang S, et al
    Serial T-SPOT.TB in household contacts of tuberculosis patients: a 6-year observational study in China.
    Int J Tuberc Lung Dis. 2019;23:989-995.
    PubMed     Abstract available


  381. FARLEY JE, McKenzie-White J, Bollinger R, Hong H, et al
    Evaluation of miLINC to shorten time to treatment for rifampicin-resistant Mycobacterium tuberculosis.
    Int J Tuberc Lung Dis. 2019;23:980-988.
    PubMed     Abstract available


  382. SMITTIPAT N, Miyahara R, Juthayothin T, Billamas P, et al
    Indo-Oceanic Mycobacterium tuberculosis strains from Thailand associated with higher mortality.
    Int J Tuberc Lung Dis. 2019;23:972-979.
    PubMed     Abstract available


  383. MISHRA B, Mohapatra PR
    Expand the RRDR hotspot to improve GeneXpert results.
    Int J Tuberc Lung Dis. 2019;23:1043.
    PubMed    


  384. HARRIES AD, Chakaya JM
    Assessing and managing pulmonary impairment in those who have completed TB treatment in programmatic settings.
    Int J Tuberc Lung Dis. 2019;23:1044-1045.
    PubMed    


  385. HARRIES AD, Timire C, Takarinda KC, Sandy C, et al
    Ensuring that Xpert((R)) MTB/RIF is used to its maximum potential.
    Int J Tuberc Lung Dis. 2019;23:1043-1044.
    PubMed    


    July 2019
  386. MARTINEZ-GIRON R, van Woerden HC
    The recognition of Lophomonas blattarum in fresh respiratory samples in recent correspondence.
    Int J Tuberc Lung Dis. 2019;23:873-874.
    PubMed    


  387. SILVA A, Ponte C, Antas PRZ
    What a difference a strain makes!
    Int J Tuberc Lung Dis. 2019;23:874.
    PubMed    


  388. NDAKIDEMI E, Emerson C, Medley A, Ngowi B, et al
    Health care worker perspectives on TB case finding and HIV services among pediatric TB patients in Tanzania.
    Int J Tuberc Lung Dis. 2019;23:811-816.
    PubMed     Abstract available


    June 2019
  389. KAMAT AS, Gretschel A, Vlok AJ, Solomons R, et al
    Reply to "Cerebrospinal fluid protein and shunt obstruction in tuberculous meningitis".
    Int J Tuberc Lung Dis. 2019;23:767-768.
    PubMed    


  390. FIGAJI A, Fieggen G, Enslin N, Taylor A, et al
    Cerebrospinal fluid protein and shunt obstruction in tuberculous meningitis.
    Int J Tuberc Lung Dis. 2019;23:765.
    PubMed    


  391. ASSEFA Y, Woldeyohannes S, Gelaw YA, Hamada Y, et al
    Screening tools to exclude active pulmonary TB in high TB burden countries: systematic review and meta-analysis.
    Int J Tuberc Lung Dis. 2019;23:728-734.
    PubMed     Abstract available


    May 2019
  392. MITCHELL EMH, Heumann SG, Sprague L, Tesfaye DH, et al
    'Reservoir of infection' or 'fount of knowledge'? Forging equal partnerships and shifting power to address LTBI.
    Int J Tuberc Lung Dis. 2019;23:527-528.
    PubMed    


  393. HAROUNA SH, Ortuno-Gutierrez N, Souleymane MB, Kizito W, et al
    Short-course treatment outcomes and adverse events in adults and children-adolescents with MDR-TB in Niger.
    Int J Tuberc Lung Dis. 2019;23:625-630.
    PubMed     Abstract available


  394. ISMAIL NA, Said HM, Rodrigues C, Omar SV, et al
    Multicentre study to establish interpretive criteria for clofazimine drug susceptibility testing.
    Int J Tuberc Lung Dis. 2019;23:594-599.
    PubMed     Abstract available


  395. BERROCAL-ALMANZA LC, Botticello J, Piotrowski H, Karnani N, et al
    Engaging with civil society to improve access to LTBI screening for new migrants in England: a qualitative study.
    Int J Tuberc Lung Dis. 2019;23:563-570.
    PubMed     Abstract available


    April 2019
  396. KYI MS, Aung ST, Oo HN, Chongsuvivatwong V, et al
    Fully vs. partially integrated services for TB-HIV in Myanmar: a health services review and a cohort study.
    Int J Tuberc Lung Dis. 2019;23:498-506.
    PubMed     Abstract available


  397. EPSTEIN RL, Bhagavathula M, Saag LA, Verma S, et al
    QuantiFERON((R))-TB Gold In-Tube reliability for immigrants with parasitic infections in Boston, USA.
    Int J Tuberc Lung Dis. 2019;23:482-490.
    PubMed     Abstract available


    March 2019
  398. BERHANU RH, Schnippel K, Kularatne R, Firnhaber C, et al
    Discordant rifampicin susceptibility results are associated with Xpert((R)) MTB/RIF probe B and probe binding delay.
    Int J Tuberc Lung Dis. 2019;23:358-362.
    PubMed     Abstract available


  399. LAI J, Dememew Z, Jerene D, Abashawl A, et al
    Provider barriers to the uptake of isoniazid preventive therapy among people living with HIV in Ethiopia.
    Int J Tuberc Lung Dis. 2019;23:371-377.
    PubMed     Abstract available


  400. KURTZ T, Feil AC, Nascimento LS, de Oliveira Abreu P, et al
    Effect of neonatal bacille Calmette-Guerin on the tuberculin skin test reaction in the first 2 years of life.
    Int J Tuberc Lung Dis. 2019;23:344-348.
    PubMed     Abstract available


  401. KYAW NTT, Kumar AMV, Kyaw KWY, Satyanarayana S, et al
    IPT in people living with HIV in Myanmar: a five-fold decrease in incidence of TB disease and all-cause mortality.
    Int J Tuberc Lung Dis. 2019;23:322-330.
    PubMed     Abstract available


    February 2019
  402. SULEIMAN K, England K, Lessem E, McKenna L, et al
    Key features to consider in revising the Model List of Essential In Vitro Diagnostics: a TB perspective.
    Int J Tuberc Lung Dis. 2019;23:272.
    PubMed    


  403. SYKES CA, Shepherd J, McGoldrick C, Kennedy N, et al
    A case of rifampicin-induced haemolysis.
    Int J Tuberc Lung Dis. 2019;23:239-240.
    PubMed     Abstract available


  404. VAN AERDE KJ, van der Heijden EHFM, Henriet SS, Merkus PJ, et al
    A case promoting use of ultrasound-guided sampling techniques to correctly diagnose MDR-TB in children.
    Int J Tuberc Lung Dis. 2019;23:236-238.
    PubMed     Abstract available


  405. RENDON A, Silva DR, Esposito S, Sotgiu G, et al
    Launching the Global TB Network.
    Int J Tuberc Lung Dis. 2019;23:123-124.
    PubMed    


    January 2019
  406. REIMANN M, Schaub D, Kalsdorf B, Runge C, et al
    Cigarette smoking and culture conversion in patients with susceptible and M/XDR-TB.
    Int J Tuberc Lung Dis. 2019;23:93-98.
    PubMed     Abstract available


  407. AGIZEW T, Boyd R, Auld AF, Payton L, et al
    Treatment outcomes, diagnostic and therapeutic impact: Xpert vs. smear. A systematic review and meta-analysis.
    Int J Tuberc Lung Dis. 2019;23:82-92.
    PubMed     Abstract available


  408. PEDRAZZOLI D, Borghi J, Viney K, Houben RMGJ, et al
    Measuring the economic burden for TB patients in the End TB Strategy and Universal Health Coverage frameworks.
    Int J Tuberc Lung Dis. 2019;23:5-11.
    PubMed     Abstract available


  409. AGGERBECK H, Ruhwald M, Hoff ST, Tingskov PN, et al
    Interaction between C-Tb and PPD given concomitantly in a split-body randomised controlled trial.
    Int J Tuberc Lung Dis. 2019;23:38-44.
    PubMed     Abstract available


  410. VAN DEUN A, Tahseen S, Affolabi D, Hossain MA, et al
    Sputum smear microscopy in the Xpert((R)) MTB/RIF era.
    Int J Tuberc Lung Dis. 2019;23:12-18.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: